02:34 , Feb 26, 2019 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A method for making iPS cells hypoimmunogenic could be used to generate allogeneic cell grafts for transplant therapies. The method involves two to three steps: simultaneous or sequential CRISPR-Cas9 (CRISPR-associated protein 9)-mediated...
00:35 , Feb 1, 2019 |  BC Innovations  |  Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
19:35 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer; melanoma Cell culture and mouse studies suggest inhibiting MHCI, MHCI components or the macrophage MHC1 binding partner LILRB1 could help treat pancreatic cancer and melanoma. In co-culture of human pancreatic neuroendocrine tumor...
01:29 , Nov 29, 2017 |  BC Extra  |  Preclinical News

Researchers identify second macrophage inhibitory pathway as target for cancer immunotherapy

In a study published in Nature Immunology , researchers at Stanford University and colleagues found blocking major histocompatibility complex class I (MHCI) or leukocyte immunoglobulin-like receptor B1 (LILRB1) promoted phagocytosis of tumor cells, suggesting the...
19:22 , Mar 23, 2017 |  BC Innovations  |  Translation in Brief

Precision-engineered CARs

A Nature study suggests inserting chimeric antigen receptor (CAR) DNA within the locus encoding T cell receptor α (TCRA) could produce less exhausted and more effective antitumor agents than the common strategy of scattering CARs...
07:00 , Sep 12, 2016 |  BioCentury  |  Emerging Company Profile

Age factors

Alkahest Inc. is identifying factors in human plasma that could serve as therapeutics or novel targets used to treat age-related conditions, including Alzheimer's disease. The newco's work stems from the lab of co-founder Tony Wyss-Coray,...
07:00 , May 2, 2016 |  BioCentury  |  Emerging Company Profile

Forward compatibility

Universal Cells Inc. is using an rAAV-based gene editing platform to create universal pluripotent stem cells for allogeneic cell therapies and transplants. The platform circumvents rejection caused by mismatched human leukocyte antigens or minor histocompatibility...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Clinical News

MiR-21: Clinical trial started

Regulus began the international ATHENA study to characterize the natural decline of renal function markers, such as glomerular filtration rate (GFR), creatinine, proteinuria and beta-2 microglobulin , in about 120 patients aged >=16 years with...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

BNC105: Phase II data

Data from 136 evaluable patients with metastatic RCC who failed prior tyrosine kinase inhibitor (TKI) therapy in the Phase II portion of the open-label, dose-escalation, international Phase I/II DISRUPTOR-1 trial showed that IV BNC105 plus...